Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-1: Tirzepatide in Obesity or Overweight
NCT07481747Phase 3Recruiting
- Sponsor
- Hudson Biotech
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in obesity, Overweight, sponsored by Hudson Biotech. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07481747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481747.